sIL-2R、IL-6在重症肌无力胸腺瘤中的表达及意义  

The Roles of sIL-2R, IL-6 in Pathogenesis of Thymoma with Myasthenia Gravis

作　　者：迟海涛[1] 金蕊[1] 丛博[1] 白鹰[1] 

机构地区：[1]大连大学附属新华医院神经内科,辽宁大连116021

出　　处：《中国医药指南》2013年第7期39-40,共2页Guide of China Medicine

摘　　要：目的探讨可溶性白细胞介素2受体(sIL-2R)、白细胞介素6(IL-6)在胸腺瘤合并MG发病机制中的作用。方法搜集胸腺切除手术的27例胸腺瘤患者的相关资料,对切除的胸腺瘤组织用免疫组化的方法,确定SIL-2R、IL-6在胸腺瘤组织中的表达情况。结果 SIL-2R细胞因子、IL-6在胸腺瘤合并MG的胸腺瘤组织呈高表达。结论可溶性白细胞介素2受体(SIL-2R)、IL-6在胸腺瘤合并MG的表达呈正相关。Objective To explore the roles of slL-2R, IL-6 in the pathogenesis of thymona with myasthenia gravis. Method A analysis of 27 cases of thymona for whom thymectomy were performed was made. The immunohistochemical staining with slL-2R, IL-6 was performed on the parrafined sections of the 27 thymona specimen. Results In the 27 thymectomy patients, slL-2R. Conclusion slL-2R, IL-6 are important in pathogenesis for thymoma with MG and may also initiate the MG＇s autoimmune reactions.

关 键 词：重症肌无力 可溶性白细胞介素2受体(SIL-2R) 白细胞介素6(IL-6) 胸腺瘤 

分 类 号：R746.1[医药卫生—神经病学与精神病学]